Karsten Suhre

Feb 2, 2024 | nature.com | Karsten Suhre |Anna Halama |Gaurav Thareja

AbstractProteogenomics studies generate hypotheses on protein function and provide genetic evidence for drug target prioritization. Most previous work has been conducted using affinity-based proteomics approaches. These technologies face challenges, such as uncertainty regarding target identity, non-specific binding, and handling of variants that affect epitope affinity binding. Mass spectrometry-based proteomics can overcome some of these challenges.

Jul 26, 2023 | nature.com | Pirro G. Hysi |Annemarie I. Luik |Karl-Heinz Ladwig |Cristina Menni |M. Arfan Ikram |Karsten Suhre | +8 more

AbstractMetabolome reflects the interplay of genome and exposome at molecular level and thus can provide deep insights into the pathogenesis of a complex disease like major depression.

Jul 20, 2023 | biorxiv.org | Karsten Suhre

New Results doi: https://doi.org/10.1101/2023.07.19.549734 AbstractProtein quantitative trait loci (pQTLs) are an invaluable source of information for drug target development as they provide genetic evidence to support protein function, suggest relationships between cis- and trans-associated proteins, and link proteins to disease where they collocate with genetic risk loci for clinical endpoints.